Примери за използване на Eu http на Български и техните преводи на Английски
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Повече информация за Европейската агенция и за Европейската седмица може да бъде намерена на следния интернет адресhttp://ew2007. osha.europa. eu http://osha. europa. eu. .
More information about the European Agency and the European Week can be found athttp://ew2007. osha.europa. eu http://osha. europa. Повече информация за Европейката агенция и Европейската седмица може да бъде намерена на адрес: http://ew2007. osha.europa. eu http://osha. europa.eu ew07flyer_bg. indd 1 ew07flyer_bg. indd 1.
More information about the European Agency and the European Week can be found athttp://ew2007. osha.europa. eu http://osha. europa.QJ-AA-13-001-BG-C Европейска сметна палата 12,rue Alcide De Gasperi 1615 Luxembourg LUXEMBOURG eca-info@eca. europa. eu http://eca. europa. eu@EUAuditorsECA EUAuditorsECA ISBN 978-92-9241-154-1.
QJ-AA-13-001-EN-C European Court of Auditors 12,rue Alcide De Gasperi 1615 Luxembourg LUXEMBOURG eca-info@eca. europa. eu http://eca. europa. eu@EUAuditorsECA EUAuditorsECA ISBN 978-92-9241-159-6.Можете също така да се абонирате за безплатния бюлетин на Европейската комисия„Социална Европа“ на адрес http://ec. europa. eu/social/e-newsletter http://eures.europa. eu http://ec. europa. eu/social.
You are also welcome to sign up to receive the European Commission's free Social Europe e-newsletter at http://ec. europa.eu/social/e-newsletter http://eures.europa. eu http://ec. europa. eu/social.(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged Когато ваксината бъде приложена на котката,?
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged How has Purevax RC been studied?Combinations with other parts of speech
Използване с съществителни
Използване със наречия
(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged антитела, началната ваксинация се забавя и започва след 12- седмична възраст?
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged How does Purevax RCP FeLV work?(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged получила ген(ДНК),?
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How has Cerezyme been studied?(44- 20) 74 18 84 00 Fax(44- 20) 74 18 86 13 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged В Приложение I е представен списък с имената на засегнатите продукти.
(44-20) 74 18 84 00 Fax(44-20) 74 18 86 13 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged.(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged активното вещество в Plavix, спира агрегацията на тромбоцитите.
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged becoming‘ sticky'.(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Какви ползи от OPATANOL са установени в проучванията?
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2009 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged OPATANOL and those of placebo?(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged самостоятелно, бяха сравнени с тези на плацебо(сляпо лечение).
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged diuretic(hydrochlorothiazide).(44- 20) 74 18 84 00 Fax(44- 20) 74 18 86 68 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©. EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Списъкът с наименованията на въпросния продукт е даден в Приложение I.
(44-20) 74 18 84 00 Fax(44-20) 74 18 86 68 E-mail:mail@emea. eu. int http://www. emea.(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Какви ползи от Ibraxion са установени в проучванията?
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has Ibraxion shown during the studies?(44- 20) 74 18 84 00 Fax(44- 20) 75 23 71 29 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Колко далеч в оценката е било заявлението към момента на оттеглянето?
(44-20) 74 18 84 00 Fax(44-20) 75 23 71 29 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What was the recommendation of the CHMP at that time?(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged мозък произвежда твърде много клетки, включващи близо 3 000 пациента с ET.
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Xagrid was not compared with any other medicine.(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged проучвания ефектите на OSSEOR са сравнени с тези на плацебо(сляпо лечение)?
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has OSSEOR shown during the studies?(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged мярка за ефективност, оценена след девет месеца, е дали счупената кост е зараснала?
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has Osigraft shown during the studies?(44- 20) 74 18 84 00 Fax(44- 20) 74 18 84 16 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged плацебо(сляпо лечение), даван с амфотерицин Б за 5 дни?
(44-20) 74 18 84 00 Fax(44-20) 74 18 84 16 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What were the major concerns that led the CHMP to recommend the refusal of the marketing authorisation?(44- 20) 74 18 84 00 Fax(44- 20) 74 18 86 13 E- mail: mail@ emea.europa. eu http:// www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Списъкът с имената на засегнатите продукти е даден в Приложение І.
(44-20) 74 18 84 00 Fax(44-20) 74 18 86 13 E-mail: mail@emea.europa. eu http://www. emea. europa. eu©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged The final opinion was converted into a Decision by the European Commission on 7 September 2007.
